Tonight Dr. Miskoff continues talks on the immune system, but this time in regards to monoclonal antibodies (mAb) from a basic and therapeutic standpoint. They are entering many trials with Eli Lilly/NIH/Regeneron and many institutions, countries, and other companies. The treatment appears very promising as an alternative to convalescent plasma, but can enough be produced fast enough? Safety and efficacy trials have to be completed first, but don’t be surprised if an FDA approval is seen within the next 6-12 months or sooner. Stay tuned for more on this and studies with healthcare providers, Covid + contacts, and/or nursing home patients to prevent Covid-19 or for prophylaxis.
This may prove to be safer and more effective than vaccines.
Related Posts
